Eli Lilly and Company (LLY)vsZevra Therapeutics Inc. (ZVRA)
LLY
Eli Lilly and Company
$1,164.79
+1.04%
HEALTHCARE · Cap: $994.92B
ZVRA
Zevra Therapeutics Inc.
$11.67
+0.52%
HEALTHCARE · Cap: $689.45M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 58447% more annual revenue ($79.67B vs $136.07M). ZVRA leads profitability with a 42.8% profit margin vs 33.5%. LLY appears more attractively valued with a PEG of 1.11. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
ZVRA
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+64.8%
Fair Value
$24.07
Current Price
$11.67
$12.40 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Keeps 43 of every $100 in revenue as profit
Strong operational efficiency at 42.3%
Revenue surging 53.3% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 27 in profit
Attractively priced relative to earnings
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 30.7x book value
Smaller company, higher risk/reward
Expensive relative to growth rate
Earnings declined 88.4%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : ZVRA
The strongest argument for ZVRA centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 42.8% and operating margin at 42.3%. Revenue growth of 53.3% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : ZVRA
The primary concerns for ZVRA are Market Cap, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ZVRA carries more volatility with a beta of 0.95 — expect wider price swings.
ZVRA is growing revenue faster at 53.3% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 63/100), backed by strong 33.5% margins and 47.7% revenue growth. ZVRA offers better value entry with a 64.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Zevra Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?